Antigen News and Research

RSS

Inovio first quarter total revenue increases to $3.1 million for 2011

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended March 31, 2011.

11 May 2011

FDA clears Meridian's new C. difficile immunoassay

Meridian Bioscience, Inc., Cincinnati, Ohio today announced that it has received clearance from the U.S. Food and Drug Administration for a new Clostridium difficile immunoassay named Premier C. difficile GDH.

11 May 2011

Pfizer presents SA3Ag staphylococcal vaccine Phase 1 trial data at ECCMID/ICC

Inhibitex, Inc., announced today that Pfizer Inc. presented safety and immunogenicity data from a Phase 1 double-blind randomized placebo controlled study in 408 healthy volunteers of a novel three antigen Staphylococcus aureus investigational vaccine at the 21st European Congress of Clinical Microbiology and Infectious Diseases and 27th International Congress of Chemotherapy in Milan, Italy.

10 May 2011

Mathematical approach can make combination vaccines more affordable for developing countries

Combination vaccines for young children are commonly used in industrialized nations because they provide protection for multiple diseases in one single injection. However, combination vaccines are prohibitively expensive for developing countries and may not available until several years later, or when market prices are more affordable.

10 May 2011

Inovio reports VGX-3100 Phase I study data in cervical dysplasia and cancer

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, has reported data demonstrating long-term durability of immune responses induced by VGX-3100, its investigational DNA vaccine for treating cervical dysplasia and cancer caused by human papillomavirus.

9 May 2011

Diamyd Medical announces European Phase III study results in type 1 diabetes

Diamyd Medical reports that results from its European Phase III study with the antigen-based therapy Diamyd did not meet the primary efficacy endpoint of preserving beta cell function at 15 months, as measured by meal stimulated C-peptide, in newly diagnosed type 1 diabetes patients.

9 May 2011

Current Opinion in Immunology journal publishes Inovio's article on DNA vaccines

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that the prestigious journal Current Opinion in Immunology has published an article in its current issue entitled, "Electroporation Delivery of DNA Vaccines: Prospects for Success."

7 May 2011

Study offers means of activating T cells to fight disease without antigenic triggers

For much of the time our T cells-the white blood cells that act as the police of the immune system-are in what immunologists call a "quiescent state," a sort of standby mode. For years, scientists have wondered if quiescence occurred by default or whether T cells need to work at remaining silent.

6 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

Bill & Melinda Gates Foundation announces 88 new winners under Grand Challenges Exploration program

The Bill & Melinda Gates Foundation today announced 88 new winners of US$100,000 each to support innovative research that has the potential to dramatically improve lives in some of the world's poorest countries. The funding, made possible through the Grand Challenges Exploration (GCE) program, will enable researchers worldwide to test unorthodox ideas that address persistent health and development challenges.

30 Apr 2011

Researchers discover possible role of SCCA in breast cancer progression

In an analysis of more than 1,300 human breast tissue samples, a team of Stony Brook University School of Medicine researchers discovered a possible role of the squamous cell carcinoma antigen in the progression of breast cancer.

29 Apr 2011

Simple blood test can diagnose early Parkinson's disease

In Parkinson's disease, the human body generates antibodies to combat the amyloid-producing protein alpha synuclein early in the course of the disease. A simple blood test that measures these antibodies can facilitate early diagnosis of the disorder, writes Ludmilla Morozova-Roche and her associates at Umeå University in Sweden in the latest issue of the journal PLoS One.

28 Apr 2011

Seattle BioMed study to identify biomarkers for malaria vaccine design

In the first study of its type in the malaria field, Seattle BioMed has been awarded an $8.9 million grant from the Bill & Melinda Gates Foundation to identify biomarkers that will allow malaria vaccine design based on robust predictors of protective immunity.

28 Apr 2011

Tarix begins patient enrollment for TXA127 Phase 1 study in DCBT

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 1 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

27 Apr 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

Signaling pathway reveals mechanism for B cell differentiation in immune response

An article in Science Signaling by researchers at the RIKEN Research Center for Allergy and Immunology (RCAI) has clarified for the first time the mechanism governing differentiation of B cells into antibody-producing plasma cells. The finding establishes a role for the extracellular signal-regulated kinase (ERK) signaling pathway in B cell differentiation, a key step toward the development of B cell-targeted drugs for treatment of autoimmune diseases and allergies.

25 Apr 2011

Congressman Holt congratulates Vaxinnate for BARDA award to develop next generation of flu vaccines

U.S. Congressman Rush Holt (R-12th) visited the headquarters of VaxInnate Corporation today, where he congratulated the biotechnology company on having received a U.S. government contract to fund development of the next generation of flu vaccines and called for more technology investments to improve the health of all Americans.

22 Apr 2011